Aspirin resistance in arthroplasty patients

  • Research type

    Research Study

  • Full title

    Aspirin resistance in patients undergoing primary hip and knee arthroplasty: a case-control study

  • IRAS ID

    292670

  • Contact name

    John McLoughlin

  • Contact email

    john.mcloughlin2@nhs.scot

  • Sponsor organisation

    Univeristy of Aberdeen and NHS Grampian

  • Duration of Study in the UK

    0 years, 6 months, 30 days

  • Research summary

    Approximately every 1 in 1500 people undergoing hip and knee replacement surgery will die of a blood clot on the lungs following surgery. Medications are usually given to try prevent these clots from happening, with Aspirin one of the most common drugs used for this purpose. Aspirin has shown to be widely effective in preventing blood clots, but it has previously been recognised that the drug might not work properly for certain individuals. This is known as aspirin ‘resistance’. We set out to establish whether patients who underwent joint surgery in Aberdeen from 2017-2020 and went on to develop clots can be classed as aspirin resistant using a blood test. The rate of resistance in this group will then be compared to a larger group of patients without a history of blood clots who are attending a pre-assessment clinic for joint replacement surgery. The data obtained from the study could highlight an important link between aspirin resistance and the likelihood of going on to develop a clot post-surgery. The information gathered in the study could help inform clinicians as to the most efficacious method of preventing clots for each individual, allowing for more targeted approach to clot prevention.

  • REC name

    North East - Newcastle & North Tyneside 2 Research Ethics Committee

  • REC reference

    22/NE/0033

  • Date of REC Opinion

    11 Jan 2023

  • REC opinion

    Further Information Favourable Opinion